1 June 2012 
EMA/337053/2012 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Pradaxa 
dabigatran etexilate mesilate 
On 01 June 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a variation to the terms of the marketing authorisation for the medicinal 
product Pradaxa. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim 
International GmbH. They may request a re examination of the CHMP opinion, provided that they 
notify the European Medicines Agency in writing of their intention within 15 days of receipt of the 
opinion. 
The CHMP adopted a change to a contraindication as follows2: 
 
“Organic lesion at risk of bleeding  Lesion or condition at significant risk of major 
bleeding such as current or recent gastrointestinal ulceration, presence of malignant 
neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or 
ophthalmic surgery, recent intracranial haemorrhage, known or suspected 
oesophageal varices, arteriovenous malformations, vascular aneurysms or major 
intraspinal or intracerebral vascular abnormalities 
 
Spontaneous or pharmacological impairment of haemostasis  Concomitant treatment 
with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular 
weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), 
oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under the 
circumstances of switching therapy to or from Pradaxa (see section 4.2) or when UHF 
is given at doses necessary to maintain an open central venous or arterial catheter 
(see section 4.5)” 
Detailed conditions for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
2 The text in bold represents the amended contraindication, the text strikethrough represents the deleted contraindication 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7523 7455 
E-mail  info@ema.europa.eu  Website  www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
                                               
(EPAR), and will be available in all official European Union languages after the variation to the 
marketing authorisation has been granted by the European Commission. 
For information, the full contraindication(s) for Pradaxa will be as follows: 
 
 
 
 
“Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
Patients with severe renal impairment (CrCL < 30 ml/min) (see section 4.2) 
Active clinically significant bleeding 
Lesion or condition at significant risk of major bleeding such as current or recent gastrointestinal 
ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal 
injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or 
suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major 
intraspinal or intracerebral vascular abnormalities 
 
Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), 
low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux 
etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under the circumstances 
of switching therapy to or from Pradaxa (see section 4.2) or when UHF is given at doses 
necessary to maintain an open central venous or arterial catheter (see section 4.5)” 
Hepatic impairment or liver disease expected to have any impact on survival 
Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole and tacrolimus 
 
 
(see section 4.5)” 
Pradaxa 
EMA/337053/2012  
Page 2/2
 
 
 
 
 
